Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation

Jul 8, 2019 | Press Releases

You May Also Like

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

0 Comments

Others News

Scots heart patients first in world to trial new treatment
Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation

Stay Updated

Sign up for our email list below to receive periodic updates from SQ Innovation, Inc. on the Lasix SQF Infusion as we continue development and go to market.

Thank you! You have successfully subscribed!

Stay Updated

Sign up for our email list below to receive periodic updates from SQ Innovation, Inc. on the Lasix SQF Infusion as we continue development and go to market.

You have Successfully Subscribed!